PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT05037409
- Locations
- 🇯🇵
Medical Corporation Shinanokai Shinanozaka Clinic, Shinjuku-ku, Tokyo, Japan
A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 129
- Registration Number
- NCT05036512
- Locations
- 🇦🇺
Harry Perkins Institute of Medical Research, Nedlands, Western Australia, Australia
🇦🇺Linear Clinical Research, Nedlands, Western Australia, Australia
🇺🇸ICON Early Phase Services, LLC, San Antonio, Texas, United States
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
- Conditions
- Lower Respiratory Tract Illness
- Interventions
- Biological: Placebo
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 38567
- Registration Number
- NCT05035212
- Locations
- 🇺🇸
St. Vincent's Birmingham (Pharmacy), Birmingham, Alabama, United States
🇺🇸St. Vincent's Birmingham, Birmingham, Alabama, United States
🇺🇸Medical Affiliated Research Center, Huntsville, Alabama, United States
Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2022-07-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT05032690
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05032950
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
Korea Comirnaty Post-marketing Surveillance
- Conditions
- COVID-19VaccinesSARS-CoV-2SafetyAdverse Effects
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12000
- Registration Number
- NCT05032976
- Locations
- 🇰🇷
Pfizer Inc, Seoul, Korea, Republic of
Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea
- Conditions
- Venous Thromboembolism
- Interventions
- Drug: Parenteral anticoagulant
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 55759
- Registration Number
- NCT05022563
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
🇰🇷Sungkyunkwan University, Suwon-si, Korea, Republic of
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
- Conditions
- Breakthrough InfectionCovid-19ImmunosuppressedSARS-COV-2 InfectionImmunocompromisedSARS-COV-2
- Interventions
- Biological: BNT162b2 (Tozinameran)
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1277747
- Registration Number
- NCT05020145
- Locations
- 🇺🇸
Pfizer Inc., New York, New York, United States
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 944
- Registration Number
- NCT05020236
- Locations
- 🇺🇸
Clovis Community Medical Center, Clovis, California, United States
🇺🇸Community Cancer Institute, Clovis, California, United States
🇺🇸University of California San Francisco, Fresno, California, United States
A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT05014412
- Locations
- 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Poudre Valley Hospital, Fort Collins, Colorado, United States